We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...

CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co ... in-class innovative ADC drug SKB518 from the United States Food and Drug Administration (FDA).

United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and ...

CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company ... its potential first-in-class innovative ADC drug SKB518 from the United States Food ...

(Geneva, April 3, 2025) – The United Nations Human Rights Council on April 3, 2025, began an intergovernmental process to draft an international human rights treaty on older people, Human Rights ...

It will also pay $200 million for United Biotechnology’s UBT251, a triple agonist for GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors.—LAURA HOWES Circular ...

UNITED LAB (03933.HK) announced that it had entered into an exclusive licensing agreement with its wholly-owned subsidiary United Biotechnology and Novo Nordisk for ...

United States: Favorable government support transforms the biotech sector in the U.S. Government agencies like USDA, EPA, and FDA regulate biotech products for agriculture, environment ...

To Leerink Partners, the deal validates Lexicon’s obesity platform while providing the biotech with financial flexibility to focus on its other cardiometabolic drugs. In a note sent to investors ...

United Biotechnology, a subsidiary of The United Laboratories, will retain the rights to UBT251 in those regions. Please watch the video at Investors.com - The Weight-Loss Drug Market Is Hot.

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...